Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Translational specialization of cellular identity in embryonic development and disease

Project description

Exploring translational specialisation factors’ role in cardiac diseases

How genetic information is translated into cell fate decisions is a central question in developmental biology. The ERC-funded TRANSCEND project investigates how cells selectively control protein production over time and space to drive human heart development. Focusing on specialised regulators of translation, the project will uncover how these factors shape key developmental transitions and guide cardiac cell identity and function. It will combine cutting-edge experimental and computational approaches to map translational control programmes in health and disease and to test whether they can be harnessed to counter pathological cardiac remodelling. The findings will contribute to the development of innovative therapies to restore cardiac function.

Objective

A central question in developmental biology is how the genetic information is differentially interpreted to program cell-fate decisions essential for embryogenesis. The success of developmental cell-fate decisions relies on the accurate rewiring of the proteome to support rapid cellular identity changes. Here, we will address the fundamental question: How is the developmental transcriptome differentially translated in time and space to program cell-fate decisions? I hypothesize that the developmental competence for cell-fate decisions is controlled by fate-specific translational specialization factors (TSFs). TSFs program the selective and privileged translation of developmental genes in defined time windows to enable the acquisition of cell fate and maintenance of cellular identity. Notably, in a proof-of-principle study, we discovered that translational specialization in pluripotency poises future lineage choices in humans. The research program TRANSCEND has four work packages: (1) identifying candidate TSFs engineering cardiac fate at critical cell-fate transitions by cell-fate specific, systematic cataloging TSFs on ribosomal complexes; (2) dissecting the molecular and functional role of TSFs in cardiac cell-fate specification by combining targeted CRISPR screens and tethered functional approaches; (3) decoding the mechanisms, modalities, and design principles by which TSFs program cardiac identity by using a holistic approach, including loss-of-function studies in cardiac 2D, organoid, and mouse models along with systems-wide methods such as eCLIP-seq and TCP-seq; and (4) engineering translation specialization modules to ameliorate pathological cardiac hypertrophy using patient-derived in vitro and murine in vivo models. Ultimately, the proposed research program TRANSCEND aims at transforming our current understanding of translational control over cell-fate decisions and opening up innovative avenues for controlled therapeutic restoration of cardiac function.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2021-COG

See all projects funded under this call

Host institution

JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN
Net EU contribution
€ 1 801 739,92
Address
THEODOR W ADORNO PLATZ 1
60323 Frankfurt Am Main
Germany
Region
Hessen Darmstadt Frankfurt am Main, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 801 739,92

Beneficiaries (1)